XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 3 Months Ended 7 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Jul. 31, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Collaboration And Other Agreements [Line Items]              
Revenues $ 41,734 $ 15,662   $ 78,842 $ 63,300    
Deferred revenue, current 7,085     7,085   $ 20,646  
Deferred revenue, net of current portion 5,084     5,084   0  
I-Mab | I-Mab Biopharma Collaboration and License Agreement              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment             $ 15,000
Development and regulatory milestones recognized       5,000   5,000  
Estimated variable consideration             $ 1,000
Revenues 3,800 5,500   4,500 $ 7,900    
Deferred revenue 0     0   4,500  
One Time Millstone Credit           $ 4,500  
I-Mab | I-Mab Biopharma Collaboration And License Agreement Clinical Supply              
Collaboration And Other Agreements [Line Items]              
Revenues 300     1,500      
Incyte Corporation | RevenuesFromCMOAgreementsMember              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment     $ 10,000        
Revenues   $ 1,100   5,100      
Deferred revenue 9,500     9,500      
Deferred revenue, current 4,400     4,400      
Deferred revenue, net of current portion $ 5,100     $ 5,100